Prothena (PRTA)
(Delayed Data from NSDQ)
$22.52 USD
-0.87 (-3.72%)
Updated May 17, 2024 04:00 PM ET
After-Market: $22.34 -0.18 (-0.80%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 81 - 100 ( 329 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Did you Know Prothena has an Anti-Abeta Antibody with Superior Binding Profile? Reit Buy and Raising PT $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Dynamic Pipeline Keeps its Focus on Protein Misfolding Diseases; Reit Buy and $33 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Implications of the SPARK trial data for Prasinezumab and Resurgence of Birtamimab Our Thoughts; PT up to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Return of the Birtamimab¯Bolstering Prothena''s Rich Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Positive Data From Prothenas Phase 1 Long-Term Extension Study of PRX004¯Hope for ATTR-CM Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department